Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

NDAC Member Resigns Over Plan B; Other Committees Discuss Departures

This article was originally published in The Tan Sheet

Executive Summary

Former Nonprescription Drugs Advisory Committee member Frank Davidoff, MD, no longer plans to advise other committee members to resign from their duties in protest of the agency's handling of the Barr Labs' Plan B switch application

You may also be interested in...



FDAer Resigns Over Plan B; Senators Seek Results Of GAO Investigation

FDA Office of Women's Health Director Susan Wood is resigning over the agency's handling of Barr Labs' application to switch its Plan B emergency contraceptive over-the-counter

FDA “Unable” To Decide On Plan B, Seeks Comment On Dual-Status Drugs

FDA believes additional information on whether a drug can be marketed both Rx and OTC for the same indication is needed before a decision can be reached on Barr Labs' switch application for Plan B

People In Brief

Perrigo promotes in pricing, planning

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS098714

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel